Epidemiology and diagnosis of acute pulmonary embolism Dr Sam Z Goldhaber Associate Professor of Medicine Harvard Medical School Staff Cardiologist Brigham.

Slides:



Advertisements
Similar presentations
Viral vents his frustration with.  What the d-dimer actually measures  Usual applications of d-dimer  Interesting applications of d-dimer  How to.
Advertisements

VTE Toolkit Chapter Five Venous Disease Coalition
Deep venous thrombosis and pulmonary embolism in pregnancy Petr Krepelka, 2013.
Thromboembolic complications in IBD
Diagnosing Pulmonary Embolism in 2003 Dr. Peter Jones Emergency Medicine Specialist Auckland Hospital.
+ Deep Vein Thrombosis Common, Preventable, and potentially Fatal.
Results: 1.Progression of thrombus length and volume (40% vs. 28%; P
Bleeding and Thrombosis in Children Alice J. Cohen, M.D. Newark Beth Israel Medical Center.
RecommendationsRecommendations Risk Recommendation Ambulation (all pts) IPC/GCS or, UFH 5000 SQ q 12 hrs or, Enoxaparin 40mg SQ daily IPC/GCS or, UFH 5000.
Risk of VTE – when is anticoagulation required treatment of VTE – what is optimum anticoagulant survival advantage with heparins new anticoagulants – how.
Venous Thromboembolism: Risk Factors, Assessment, & Prevention
Below the Knee DVT and Pregnancy Related Thrombosis Robert Lampman, MD Morning Report July 2009.
Week 6: Secondary Hemostasis Plasmatic factors Plasmatic factors Intrinsic pathway Intrinsic pathway Extrinsic pathway Extrinsic pathway Specimen Specimen.
Week 7: Fibrinolysis and Thrombophilia Secondary fibrinolysis Secondary fibrinolysis Primary fibrinolysis Primary fibrinolysis Plasminogen Plasminogen.
How do you approach a patient you think may have a PE?
Cerebral Vein Thrombosis Morning Report Sima Patel 5/13/09.
Venous thromboembolism: how long to treat?
D-dimer in the Diagnosis of Pulmonary Embolism Cheryl Pollock PGY-3.
© Siemens All rights reserved. The Clinical Utility of D-dimer Assays Beth Phillips MT,SH (ASCP) Zone Technical Application Specialist Siemens Healthcare.
Chapter Two Venous Disease Coalition Pathogenesis and Consequences of VTE VTE Toolkit.
Thrombophilia For the Clinician
Thrombophilias Sharon Sams. Objectives Overview of etiology of hypercoagulability Available tests Clinical correlation or “What do I do with these results?”
DVT: Symptoms and work-up Sean Stoneking. DVT Epidemilogy Approximately 600,0000 new cases of DVT each year 50% in hospitalized patients or nursing home.
By Maisa Mansour, MD Pulmonary medicine JUH
Extended Anticoagulation in VTE Geoffrey Barnes, MD Cardiovascular and Vascular Medicine University of Michigan, USA 1 st Qatar Conference on Safe Anticoagulation.
Epidemiology and diagnostic tests for venous thromboembolism Edwin JR van Beek, MD PhD FRCR Section of Academic Radiology University of Sheffield, UK.
Thrombophilia— Hypercoagulable States Gabriel Shapiro, MD, FACP.
Prospective evaluation of Innovance D-dimer in the exclusion of venous thromboembolism [VTE]. Robert Gosselin, CLS Department of Clinical Pathology and.
Venous complications in pregnancy and puerperium ASSOCIATE PROFESSOR IOLANDA ELENA BLIDARU MD, PhD.
Renal vein thrombosis Nephrology discussion Dr. Coetser Prof. Van Rensburg and dr. Rossouw.
Pulmonary Embolism and Infarction
Spotlight Case May 2003 Central Line Complications in an Infant webmm.ahrq.gov.
DEFINING THE DURATION OF ANTICOAGULATION. HOW LONG TO TREAT A DVT?
Case Report Pneumology Dr. David Tran A&E, FVHospital Medical meeting September 28 th, 2011.
Thrombophilia Testing Robert Gosselin MT (ASCP), CLS.
Hypercoagulable Syndromes. Risk Factors For Venous Thrombosis ACQUIREDINHERITEDMIXED/UNKNOWN Advancing ageAntithrombin Deficiency  Homocysteine ObesityProtein.
Tabuk University Faculty of Applied Medical Sciences Department Of Medical Lab. Technology 3 rd Year – Level 5 – AY
Thrombophilia National Haemophilia Director
Dr. Meg-angela Christi Amores
PULMONARY EMBOLI Kenney Weinmeister M.D.. PULMONARY EMBOLI w Over 500,000 cases per year. w Results in 200,000 deaths. w Mortality without treatment is.
Thrombophilia (Hypercoagulable States) Abdulkareem Almomen, MD Professor of Medicine & Hematology, King Saud University MED 341, Feb.2014.
Thrombophilia. Definition –Tendency to develop clots due to predisposing factors that may be genetically determined.
Charles J. Lockwood, M.D. The Anita O’Keefe Young Professor and Chair Department of Obstetrics, Gynecology and Reproductive Sciences Yale University School.
Deep vein thrombosis Pulmonary embolism Deep vein thrombosis Pulmonary embolism Venous Thromboembolism TreatmentTreatment …All the same?
Acute Venous Pulmonary Embolism Restore cardiopulmonary hemodynamics Avoid recurrence Avoid chronic thromboembolic pulmonary hypertension Restore cardiopulmonary.
Venous thromboembolic disease
Duration of Anticoagulation 5 Patients Categories 3. First Episode: 4. First Episode: 5.Recurrent DVT 2. First Episode: 1. First Episode: Transient risk.
PE Clinical Evaluation. Presenting Complaint Most common presenting complaint: dyspnoea Chest pain Syncope Cough Leg pain.
Prof. Mona Mansour Professor of Pulmonary Medicine Ain Shams University.
Issues in diagnosis of VTE in Pregnancy Ng Heng Joo Department of Haematology Singapore General Hospital.
M.A.ZOHAL PULMUNOLOGIST
Managing suspected pulmonary embolism in primary care Referral for all? G.J. Geersing, M.D. PhD. Julius Center for Health Sciences and Primary Care EPCCS.
Congenital Thrombophilias: an overview
Deep vein thrombosis and pulmonary embolism.
PULMONARY EMBOLISM BY Dr. Hayam Hebah Associate professor of internal medicine AL-Maarefa College.
Hypercoagulable States
Coagulation disorders in pregnancy. Hematological Changes During Pregnancy: 1-Expansion of plasma volume and hemodilution. 2-Hb level increases, but there.
Pulmonary Embolism Dr. Gerrard Uy.
Venous Thromboembolic Disease: The Role of Novel Anticoagulants Grant M. Greenberg MD, MA, MHSA.
Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: Management of Pulmonary Embolism: An Update J Am.
Date of download: 6/22/2016 From: An Evaluation of d-Dimer in the Diagnosis of Pulmonary Embolism: A Randomized Trial Ann Intern Med. 2006;144(11):
Asad Mehdi, MD. Outline A Diagnostic Approach to Pulmonary Embolism Clinical Presentation Risk Stratification Wells Criteria Geneva Rule PIOPED Approach.
By : Saad Gharaibeh Anwar Al-Kassar Samah Telfah Abd-elsalam Sleman Venous Thrombo-embolism (VTE) 1.
Presentation by: AFSAR FATHIMA M.Pharm.
Venous Thromboembolism Prophylaxis for Medical Inpatients
By: Dr. Nalaka Gunawansa
The Evaluation of Suspected Pulmonary Embolism
Pulmonary Embolism 101 Alex Rankin, MD.
Pulmonary Thrombo-Embolism
Stavros V. Konstantinides et al. JACC 2016;67:
Presentation transcript:

Epidemiology and diagnosis of acute pulmonary embolism Dr Sam Z Goldhaber Associate Professor of Medicine Harvard Medical School Staff Cardiologist Brigham and Women’s Hospital Boston, MA

Risk factors for PE Nurses’ Health Study 1)Obesity (RR = 3.0, with BMI >29) 2)Cigarette smoking (RR = 2.1, with > 35 cigs/d) 3)Hypertension (RR = 1.5) JAMA 1997; 277:642

Hypercoagulability work-up High yield (> 20%) 1)Factor V Leiden – Genetic mutation that causes resistance to activated protein C 2)Plasma homocysteine level – Rx with folate, B6, B12 3)Lupus anticoagulant screen – Requires intensive anticoagulation; Possible steroid/ASA responsiveness

Leiden/recurrent VTE after discontinuing warfarin RR = 4.7 (p = 0.047) (PHS: Circulation 1995; 92:2800) RR = 2.4 (p < 0.01) (Padua: NEJM 1997; 336:399) No increased risk (Rintelen: Thromb Haemostas 996; 75:229)

ACLA and VTE 412 Swedish patients 14%  ACLA in men 17%  ACLA in women 29% recurrence in ACLA positive vs 14% recurrence in ACLA negative 15% vs 6% 4-year mortality Am J Med 998; 104:332

Prothrombin gene mutation risk DVT/PE (Ann Intern Med 1998; 129:89)  risk cerebral vein thrombosis (NEJM 1998; 338:1793)

Hypercoagulability work-up Low yield 1)antithrombin III deficiency (spurious value on heparin) 2)protein C deficiency (spurious value on warfarin, BCP or when pregnant) 3)protein S deficiency (spurious value on warfarin, BCP or when pregnant)

Signs/Sx PE (n = 131) ObservationRate Dyspnea77% Chest pain55% Cyanosis18% Hemoptysis13% Syncope10% Arch Intern Med 1991; 151:933

BLOOD ACTIVATION fibrinogenfibrin monomersfibrin clot thrombin F XIII F XIIIa plasmin FDP fibrinogen degradation products FIBRINOLYSIS D-Dimers (XDP) Figure 1: D-Dimer is exclusively from fibrin clot DD

D-Dimer for PE diagnosis Overview of 9 trials (n = 908) ELISA assay; 38% have positive scans/PAgrams Sensitivity Specificity PPV NPV 97% 45% 50% 94% Thromb Haemostas 1994; 71:1-6

High probability lung scans are insensitive for PE Scan interpretationSensitivity (%)Specificity (%) High % of patients with PE have non-high probability scans JAMA 1990; 263:2753-9

Normal (left) and abnormal (right) venous ultrasounds (C = compression)

Venography for suspected PE Venography Pulmonary angiography PositiveNegative Positive2911 Negative1222 Total4133 Hull et al. Ann Intern Med 1983; 98:891

CT scan with contrast showing main bilateral pulmonary embolism

Echocardiogram suggesting a PE. Diastole on the left, systole on the right

PE diagnosis strategy High probability TREAT High D-dimer CONTINUE W/U Normal D-dimer STOP W/U If leg U/S normal PAgram (or CT) If Echo normal PAgram (or CT) Intermediate or low probability Normal STOP W/U Lung (or CT) scan